We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
RYSTIGGO (UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia)
Product name
RYSTIGGO
Date registered
Evaluation commenced
Decision date
Approval time
204 (255 working days)
Active ingredients
rozanolixizumab
Registration type
NCE/ NBE
Indication
Rystiggo is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.